Debjit Chattopadhyay
Stock Analyst at Guggenheim
(4.61)
# 225
Out of 5,149 analysts
117
Total ratings
59.26%
Success rate
22.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $224 → $284 | $258.81 | +9.73% | 5 | Feb 25, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $106 → $86 | $59.74 | +43.96% | 5 | Feb 25, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $41 → $45 | $32.83 | +37.07% | 2 | Feb 19, 2026 | |
| PEPG PepGen | Maintains: Buy | $6 → $7 | $6.53 | +7.20% | 3 | Feb 18, 2026 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $20 | $11.68 | +71.23% | 1 | Feb 11, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $64 → $52 | $23.02 | +125.89% | 4 | Jan 5, 2026 | |
| RZLT Rezolute | Maintains: Buy | $15 → $6 | $3.14 | +91.08% | 4 | Dec 12, 2025 | |
| PHVS Pharvaris | Maintains: Buy | $32 → $39 | $28.00 | +39.29% | 1 | Dec 4, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $28 → $43 | $26.51 | +62.20% | 8 | Nov 18, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $22 → $19 | $16.32 | +16.42% | 7 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $7.13 | +320.76% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $95 | $10.50 | +804.76% | 7 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $92 | $81.96 | +12.25% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $34 | $45.61 | -25.45% | 3 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $106 | $39.06 | +171.38% | 5 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $10 | $8.78 | +13.90% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $14 | $15.44 | -9.33% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $558 → $546 | $486.03 | +12.34% | 8 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $16.15 | +209.60% | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $55 | $28.69 | +91.70% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $4.66 | +286.27% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $10.83 | +56.97% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $14.36 | +4.46% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $60.77 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.33 | +338.80% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.15 | +430.12% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $2.65 | +994.34% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $325.07 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $4.53 | +518.10% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $13.85 | +44.40% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $34.09 | +260.81% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $23.31 | +131.66% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.16 | +5,072.41% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $29.20 | - | 3 | Jun 26, 2017 |
Krystal Biotech
Feb 25, 2026
Maintains: Buy
Price Target: $224 → $284
Current: $258.81
Upside: +9.73%
BioMarin Pharmaceutical
Feb 25, 2026
Maintains: Buy
Price Target: $106 → $86
Current: $59.74
Upside: +43.96%
NewAmsterdam Pharma Company
Feb 19, 2026
Maintains: Buy
Price Target: $41 → $45
Current: $32.83
Upside: +37.07%
PepGen
Feb 18, 2026
Maintains: Buy
Price Target: $6 → $7
Current: $6.53
Upside: +7.20%
Entrada Therapeutics
Feb 11, 2026
Initiates: Buy
Price Target: $20
Current: $11.68
Upside: +71.23%
Ultragenyx Pharmaceutical
Jan 5, 2026
Maintains: Buy
Price Target: $64 → $52
Current: $23.02
Upside: +125.89%
Rezolute
Dec 12, 2025
Maintains: Buy
Price Target: $15 → $6
Current: $3.14
Upside: +91.08%
Pharvaris
Dec 4, 2025
Maintains: Buy
Price Target: $32 → $39
Current: $28.00
Upside: +39.29%
Centessa Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $28 → $43
Current: $26.51
Upside: +62.20%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Buy
Price Target: $22 → $19
Current: $16.32
Upside: +16.42%
Oct 15, 2025
Initiates: Buy
Price Target: $30
Current: $7.13
Upside: +320.76%
Sep 25, 2025
Maintains: Buy
Price Target: $28 → $95
Current: $10.50
Upside: +804.76%
Sep 23, 2025
Maintains: Buy
Price Target: $90 → $92
Current: $81.96
Upside: +12.25%
Sep 15, 2025
Maintains: Buy
Price Target: $19 → $34
Current: $45.61
Upside: -25.45%
Aug 27, 2025
Reiterates: Buy
Price Target: $106
Current: $39.06
Upside: +171.38%
Aug 14, 2025
Maintains: Buy
Price Target: $40 → $10
Current: $8.78
Upside: +13.90%
Aug 13, 2025
Maintains: Buy
Price Target: $45 → $14
Current: $15.44
Upside: -9.33%
Aug 6, 2025
Maintains: Buy
Price Target: $558 → $546
Current: $486.03
Upside: +12.34%
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $16.15
Upside: +209.60%
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $28.69
Upside: +91.70%
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $4.66
Upside: +286.27%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $10.83
Upside: +56.97%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $14.36
Upside: +4.46%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $60.77
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $4.33
Upside: +338.80%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $4.15
Upside: +430.12%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $2.65
Upside: +994.34%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $325.07
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $4.53
Upside: +518.10%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $13.85
Upside: +44.40%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $34.09
Upside: +260.81%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $23.31
Upside: +131.66%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.16
Upside: +5,072.41%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $29.20
Upside: -